DRW Securities’s Larimar Therapeutics LRMR Stock Holding History

DRW Securities’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,333	Closed	-$164K	–	81
2018 Q2	$164K	Buy	1,333 +416	+45%	+$35.3K	0.01%	78
2018 Q1	$82K	Buy	917 +84	+10%	+$7.12K	0.01%	151
2017 Q4	$46K	Hold	833	–	–	﹤0.01%	451
2017 Q3	$35K	Hold	833	–	–	0.01%	61
2017 Q2	$35K	Buy	+833	New	+$42.6K	0.01%	67
2016 Q4	–	Sell	-5,833	Closed	-$232K	–	83
2016 Q3	$232K	Buy	+5,833	New	+$265K	0.02%	66

Other funds holding LRMR

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

DRW Securities's LRMR Position: Q3 2018 in Review

DRW Securities sold out of Larimar Therapeutics (LRMR) in Q3 2018, closing a stake of 1,333 shares — an estimated $164K sold.

DRW Securities first reported a position in LRMR in Q3 2016 and held it in 6 quarters. The position peaked at $232K in Q3 2016. 89 funds tracked by Wall St. Rank hold LRMR as of Q3 2018.

DRW Securities reported no remaining Larimar Therapeutics position as of Q3 2018 after selling out during the quarter.
DRW Securities sold 1,333 Larimar Therapeutics shares in Q3 2018, an estimated $164K.
DRW Securities first reported a position in Larimar Therapeutics in Q3 2016 and held it in 6 quarters.
DRW Securities's Larimar Therapeutics position peaked at $232K in Q3 2016.
89 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2018.

Based on DRW Securities's 13F filing for Q3 2018, filed 14 Nov 2018.